Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
Final hours: unlock premium data with Claim 60% OFF
AstraZeneca gets another US approval for Lynparza
Published Jun 01, 2023 10:55
AstraZeneca gets another US approval for Lynparza
Sharecast - The FTSE 100 pharmaceuticals giant said the approval was based on a subgroup analysis conducted during the phase three ‘PROpel’ trial.
It said the analysis showed that the combination of Lynparza and abiraterone demonstrated significant clinical improvements in both radiographic progression-free survival (rPFS) and overall survival (OS) compared to the use of abiraterone alone in patients with BRCA mutations.
Prostate cancer is the second most common cancer among men, AstraZeneca PLC (LON:AZN) explained, and despite the availability of several therapies for patients with mCRPC, the five-year survival rate remains low.
About 10% of patients with mCRPC have BRCA mutations, which are associated with a poor prognosis and outcomes.
The PROpel trial included 387 patients with mCRPC, of which 245 had deleterious or suspected deleterious BRCA mutations.
AstraZeneca said the trial's primary endpoint was radiographic progression-free survival, and the secondary endpoints included overall survival, time to pain progression, and time to subsequent antineoplastic therapy.
This approval followed the accelerated approval granted by the US Food and Drug Administration (FDA) in 2020 for Lynparza as a monotherapy for the treatment of patients with mCRPC who have BRCA mutations.
“There is a critical unmet need for new first-line treatment options for patients with BRCA-mutated metastatic castration-resistant prostate cancer and this approval underscores the importance of BRCA testing at metastatic diagnosis,” said Dave Fredrickson, executive vice-president of the oncology business unit.
“We look forward to bringing the benefit of this Lynparza combination to patients earlier in their treatment.”
At 0958 BST, shares in AstraZeneca were up 0.75% at 11,748p.
Reporting by Josh White for Sharecast.com.
Related Articles
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.